Ozmosi | Imiglitazar Drug Profile
Drug Profile
Using advanced filters...

Imiglitazar

Alternative Names: imiglitazar, tak-559
Clinical Status: Inactive
Latest Update: 2012-11-12
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: PPAR-a Agonist, PPAR-g Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Takeda
Company Location: Asia Pacific
Company Founding Year: 1781
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Type 2 Diabetes

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT00759720

ORIGAMI

P3

Terminated

Type 2 Diabetes

2004-12-01

2024-06-06

Primary Endpoints

NCT00762684

01-04-TL-559-028

P3

Terminated

Type 2 Diabetes

2004-12-01

2024-06-06

NCT00762957

01-04-TL-559-029

P3

Terminated

Type 2 Diabetes

2004-12-01

2024-06-06

NCT00762112

01-03-TL-559-017

P3

Terminated

Type 2 Diabetes

2004-12-01

2024-06-06

NCT00763022

01-02-TL-559-014

P3

Completed

Type 2 Diabetes

2004-12-01

2024-06-06

NCT00762190

01-03-TL-559-016

P3

Terminated

Type 2 Diabetes

2004-12-01

2024-06-06

Primary Endpoints

Recent News Events

Date

Type

Title